Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Sanofi Signs Two Bulk Drug Agreements
by Michael McCoy
July 12, 2010
| A version of this story appeared in
Volume 88, Issue 28
The French drug giant Sanofi-Aventis will carry out contract manufacturing for two biotech firms. Its Sanofi Chimie arm has signed a toll manufacturing agreement under which it will supply the Dutch company Pharming with the active ingredient in Ruconest, a protein treatment for angioedema that is soon to be launched in several European markets. Pharming says Sanofi will eventually replace Merck & Co., which now supplies Pharming with the bulk drug on a smaller scale. Separately, Sanofi will supply bulk human insulin for an oral form of insulin being developed by Israel’s Oramed Pharmaceuticals.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X